Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder: "We Don't Do That Here"
- PMID: 34090780
- PMCID: PMC9111968
- DOI: 10.1016/j.whi.2021.03.010
Reproductive-Age Women's Experience of Accessing Treatment for Opioid Use Disorder: "We Don't Do That Here"
Abstract
Purpose: For reproductive-age women, medications for opioid use disorder (OUD) decrease risk of overdose death and improve outcomes but are underutilized. Our objective was to provide a qualitative description of reproductive-age women's experiences of seeking an appointment for medications for OUD.
Methods: Trained female callers placed telephone calls to a representative sample of publicly listed opioid treatment clinics and buprenorphine providers in Florida, Kentucky, Massachusetts, Michigan, Missouri, North Carolina, Tennessee, Virginia, Washington, and West Virginia to obtain appointments to receive medication for OUD. Callers were randomly assigned to be pregnant or non-pregnant and have private or Medicaid-based insurance to assess differences in the experiences of access by these characteristics. The callers placed 28,651 uniquely randomized calls, 10,117 to buprenorphine-waivered prescribers and 754 to opioid treatment programs. Open-ended, qualitative data were obtained from the callers about the access experiences and were analyzed using a qualitative, iterative inductive-deductive approach. From all 28,651 total calls, there were 17,970 unique free-text comments to the question "Please give an objective play-by-play of the description of what happened in this conversation."
Findings: Analysis demonstrated a common path to obtaining an appointment. Callers frequently experienced long hold times, multiple transfers, and difficult interactions. Clinic receptionists were often mentioned as facilitating or obstructing access. Pregnant callers and those with Medicaid noted more barriers. Obtaining an appointment was commonly difficult even for these persistent, trained callers.
Conclusions: Interventions are needed to improve the experiences of reproductive-age women as they enter care for OUD, especially for pregnant women and those with Medicaid coverage.
Copyright © 2021 Jacobs Institute of Women's Health. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declarations of Competing Interest: The authors have no conflicts of interest to disclose.
Figures
Similar articles
-
"Just Google It": A Qualitative Study of Reproductive-Age Women's Stigmatizing Experiences When Accessing Buprenorphine for Opioid Use Disorder.Womens Health Issues. 2025 Jan-Feb;35(1):45-53. doi: 10.1016/j.whi.2024.10.003. Epub 2024 Nov 26. Womens Health Issues. 2025. PMID: 39603927
-
Barriers to accessing treatment for pregnant women with opioid use disorder in Appalachian states.Subst Abus. 2019;40(3):356-362. doi: 10.1080/08897077.2018.1488336. Epub 2018 Oct 9. Subst Abus. 2019. PMID: 29949454 Free PMC article.
-
Treatment access for opioid use disorder among women with medicaid in Florida.Drug Alcohol Depend. 2023 May 1;246:109854. doi: 10.1016/j.drugalcdep.2023.109854. Epub 2023 Mar 24. Drug Alcohol Depend. 2023. PMID: 37001322 Free PMC article.
-
Long-term treatment retention in West Virginia's comprehensive opioid addiction treatment (COAT) program.J Neurol Sci. 2020 Apr 15;411:116712. doi: 10.1016/j.jns.2020.116712. Epub 2020 Feb 3. J Neurol Sci. 2020. PMID: 32058182 Free PMC article. Review.
-
Opioid Use Disorder in Pregnancy.J Midwifery Womens Health. 2017 May;62(3):329-340. doi: 10.1111/jmwh.12619. Epub 2017 May 31. J Midwifery Womens Health. 2017. PMID: 28561914 Review.
Cited by
-
"Just Google It": A Qualitative Study of Reproductive-Age Women's Stigmatizing Experiences When Accessing Buprenorphine for Opioid Use Disorder.Womens Health Issues. 2025 Jan-Feb;35(1):45-53. doi: 10.1016/j.whi.2024.10.003. Epub 2024 Nov 26. Womens Health Issues. 2025. PMID: 39603927
-
The co-creation and evaluation of a recovery community center bundled model to build recovery capital through the promotion of reproductive health and justice.Addict Res Theory. 2024;32(6):455-465. doi: 10.1080/16066359.2023.2292589. Epub 2023 Dec 13. Addict Res Theory. 2024. PMID: 40342872 Free PMC article.
-
Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.J Gen Intern Med. 2023 Dec;38(16):3499-3508. doi: 10.1007/s11606-023-08306-0. Epub 2023 Jul 12. J Gen Intern Med. 2023. PMID: 37436568 Free PMC article.
-
Substance Use in Pregnancy: Identifying Stigma and Improving Care.Subst Abuse Rehabil. 2021 Nov 23;12:105-121. doi: 10.2147/SAR.S319180. eCollection 2021. Subst Abuse Rehabil. 2021. PMID: 34849047 Free PMC article. Review.
-
Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018.Contraception. 2023 Jan;117:67-72. doi: 10.1016/j.contraception.2022.09.129. Epub 2022 Oct 12. Contraception. 2023. PMID: 36243128 Free PMC article.
References
-
- American College of Obstetricians and Gynecologists Committee on Obstetric Practice. (2017). Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstetrics & Gynecology, 130(2), e81–e94. - PubMed
-
- Atkins DN, & Durrance CP (2020). State policies that treat prenatal substance use as child abuse or neglect fail to achieve their intended goals: Study examines the effect of state policies that treat prenatal substance use as child abuse or neglect on the incidence of neonatal abstinence syndrome and other factors. Health Affairs, 39(5), 756–763. - PubMed
-
- Azungah T. (2018). Qualitative research: deductive and inductive approaches to data analysis. Qualitative Research Journal.
-
- Bisgaier J, & Rhodes KV (2011). Auditing access to specialty care for children with public insurance. New England Journal of Medicine, 364(24), 2324–2333. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical